PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Opin Immunol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2787714
NIHMSID: NIHMS149540

Regulatory T cells and inhibitory cytokines in autoimmunity

Summary of recent advances

Foxp3+ regulatory T cells (Tregs) contribute significantly to the maintenance of peripheral tolerance, but they ultimately fail in autoimmune diseases. The events that lead to Treg failure in controlling autoreactive effector T cells (Teffs) during autoimmunity are not completely understood. In this review, we discuss possible mechanisms for this subversion as they relate to type 1 diabetes (T1D) and multiple sclerosis (MS). Recent studies emphasize (i) the role of inflammatory cytokines, such as IL-6, in inhibiting or subverting Treg function, (ii) the issue of Treg plasticity, (iii) the possible resistance of autoimmune T cells to Treg-mediated control, and (iv) Treg-associated inhibitory cytokines TGFβ, IL-10 and IL-35 in facilitating Treg suppressive activity and promoting Treg generation. These recent advances place a large emphasis on the local tissue specific inflammatory environment as it relates to Treg function and disease development.

Introduction

Autoimmunity ensues when central and/or peripheral tolerance barriers are overcome, thereby allowing the activation of self-reactive T cells, which induce tissue destruction. Most self-reactive T cells are deleted in the thymus, a process referred to as central tolerance. The few remaining self-reactive T cells that enter the periphery are controlled by peripheral tolerance mechanisms, in which Foxp3+ Tregs have emerged as the primary mediators [1]. Autoimmune disease develops when this last tolerance barrier is compromised. It has been shown that many individuals with no autoimmune manifestations harbor self-reactive T cells [2]. Thus, the continual battle between self-reactive T cells and suppressive Tregs is critical in determining whether autoimmunity commences. Many autoimmune diseases manifest themselves in an oscillating fashion, which is likely due to the aforementioned struggle between the regulatory and inflammatory arms of the immune system, suggesting that Tregs are still actively involved in regulating this self-reactive response. There are three mechanisms that might contribute to a breakdown in Treg control: (a) Treg numbers are reduced and/or Tregs are dysfunctional due to inherent deficiencies in autoimmune susceptible individuals, (b) Treg suppressive function is inhibited, diverted or converted by the chronic inflammation that occurs in autoimmunity, and/or (c) self-reactive effector T cells (Teff) become unusually aggressive and are refractory to regulation by otherwise functional Tregs because they either overwhelm regulatory control or express molecules that render them resistant. Here we will discuss how these possibilities might contribute to this loss of Treg control, illustrated by two key autoimmune diseases Type 1 Diabetes (T1D) and Multiple Sclerosis (MS), with occasional reference to other autoimmune or inflammatory diseases.

Even though multiple mechanisms of Treg-mediated suppression have been identified, the relative importance of each mechanism in vivo remains unclear [3]. Current dogma, based mostly on in vitro experiments, suggests that Treg function is contact dependent. However, a recent study illustrates that this may be inaccurate as Tregs that are optimally stimulated by contact with Teff can mediate potent third party suppression via soluble factors in vitro [4]. These data, together with significant support from in vivo observations, suggest that inhibitory cytokines such as TGFβ, IL-10, and IL-35 are major contributors to Treg function [3,5]. Consequently, this review will also focus on the contribution of these three inhibitory cytokines in mediating (or failing to mediate) Treg function in autoimmune disease.

Why do Tregs fail to suppress during autoimmune disease?

Under normal conditions, Tregs effectively inhibit excessive inflammation and autoimmune manifestations [6]. However, in autoimmune diseases Tregs fail to control the initial inflammatory insult and subsequent disease progression due to cell-intrinsic and/or cell-extrinsic factors. Studies performed in a variety of autoimmune models suggest that Tregs are still actively and continuously involved in inflammatory regulation after disease onset [7,8], although this needs to be more definitively assessed. When naturally occurring Tregs are absent in Foxp3-deficient islet antigen-specific BDC2.5 TCR transgenic NOD mice, disease onset is significantly earlier [7]. Interestingly, the rate of islet infiltration in BDC2.5 mice is similar in the presence or absence of Tregs, however, the infiltrating cells cause immediate damage in their absence [7]. In experimental autoimmune encephalomyelitis (EAE), an induced murine model of MS, Foxp3+ Tregs accumulate in the central nervous system (CNS) as the disease progresses [9] and in some instances aid in natural recovery from EAE [8]. Depletion of CD25+ T cells prior to disease induction reduces recovery rate while their depletion after recovery obliterates their protection against secondary autoimmune disease induction [10]. Although Tregs have some control over autoimmune inflammation, there may be several reasons why they ultimately fail to prevent disease progression.

Inherent defect in Treg number or function

A possible explanation for Treg failure is due to a reduction in their number and/or function in autoimmune predisposed individuals. This may not necessarily manifest systemically, and may be restricted to the site of autoimmune insult. Some studies have reported an age-related defect in NOD Treg function [11], while others were unable to detect any major deficiency [12]. In both studies Tregs were identified and isolated based on CD25 expression, which may have resulted in contamination with activated Teff thereby altering data interpretation. A more recent study took advantage of NOD Foxp3-GFP reporter mice to cleanly separate the two populations and detected no intrinsic defects in NOD Treg numbers or suppressive capabilities [13]. There is some evidence that Treg function in human patients with an early onset of diabetes might be compromised [14]. However, human studies have to rely on CD25 as a marker for Treg separation, and thus are not entirely conclusive. More recent studies were able to exclude contaminating Teff from Treg analysis based on CD127 (IL7Rα) expression that has restricted expression on activated T cells and is absent from Tregs [15,16]. Although these studies are preliminary, at least in the early diagnosed T1D patients Treg numbers appear to be decreased [16].

Treg defects at the site of inflammation

Another possibility for Treg failure is that the chronic inflammation and consequent molecular milieu at the site of autoimmune destruction could have a negative effect on Treg function. This could be manifested as a reduction in Treg inhibitory function, apoptosis, or conversion into a pro-inflammatory T cell lineage. Recently, the fate of Foxp3+ Tregs over the course of diabetes development in NOD mice was followed. Treg function at the site of inflammation was found to be diminished due to decreased levels of IL-2, a critical Treg growth factor [17]. These tissue-infiltrating Tregs were more prone to apoptosis and thus failed to control autoimmune responses. This study underlines the dependence of Treg function on local IL-2 production and the inflammatory milieu.

Treg stability and plasticity during autoimmune response has recently become a hot issue, especially since administration of in vitro differentiated Tregs is being considered for human therapy. Recent studies addressing the stability of Foxp3+ T cells have shown that both lymphopenic and inflammatory environments can result in the loss of Foxp3 expression in Tregs [1820]. The apparent plasticity of Treg lineage might result in the instability of this population during chronic autoinflammatory responses and lead to loss of Treg function in an autoimmune environment.

Clearly, Tregs possess other modes of action in addition to the three inhibitory cytokines discussed here [3,21]. There is still some controversy over the relative importance of soluble factors versus cell contact-dependent inhibition in mediating Treg function. Substantial in vivo data, together with a recent study indicate that cytokines contribute significantly to Treg function when cell contact is absent [4]. However, to unequivocally show the importance of cytokines in mediating Treg function one would have to assess inhibition in their absence. The extent of redundancy within these three inhibitory cytokines remains unclear. At first glance, it seems that there is significant overlap between the functions of the three Treg inhibitory cytokines (Figure 1). Both IL-10 and TGFβ can inhibit Th1 type responses, both are able to convert T cells into a regulatory population, albeit with quite distinct phenotypes, and all three cytokines seem to be play a role in the gut homeostasis. However, recent studies suggest that different transcriptional ‘programs’ are utilized by Tregs depending on the Th subset they are attempting to suppress which may likewise lead to the utilization of distinct suppressive functions [22,23]. Interestingly, Tregs appear to utilize similar transcription factors as the T helper cells they are suppressing, raising the possibility of a co-evolutionary progression. IRF4 deficiency in Tregs resulted in selective ablation of IL-10 transcription, partial decrease in EBI3 expression, and no affect on TGFβ. These findings suggest that Tregs may respond with a distinct inhibitory cytokine profile depending on the inflammatory milieu [22]. Thus, it is possible that further examples of Treg functional plasticity may emerge. Therefore, it is possible that although all three cytokines are utilized by Tregs in the same tissue they may control different cellular populations or that different cytokines may be more important in different organs, in a manner that cannot be fully gleaned from the studies conducted thus far. Given the brevity of cellular targets and unique microenvironments within which Tregs have to operate, it would not be surprising if there is limited functional redundancy for these cytokines, as has been suggested for IL-10 [24]. It will also be important to assess the effect of losing one inhibitory mechanism on the remaining functional landscape as it is conceivable that Tregs may make adjustments to compensate for such a loss given the functional plasticity already described.

Figure 1
Redundancy and specificity of Treg inhibitory cytokine function.

Teff resistance to inhibition

A third possibility is that highly activated self-reactive Teffs become resistant to Treg-mediated control. Studies performed in both spontaneous T1D and induced EAE models report normal Treg function during disease, but show that the Teffs are hyper activated and do not capitulate to suppression by Tregs [7,9,13,25,26]. NOD Treg function, as measured by in vitro assays, was reported to be fairly comparable to B6 Tregs. In contrast, NOD Teffs exhibited an increased ability to proliferate and were unresponsive to Treg-mediated suppression [13]. Similarly, Teffs from human T1D patients are more refractory to inhibition by Tregs than Teffs from healthy controls [27].

Mounting evidence shows that inhibitory actions of Treg-associated cytokines can be subverted in highly inflammatory environments. In particular, IL-6 has been shown to have a negative effect on Treg function [28], and in the CNS of EAE mice a typically inhibitory cytokine TGFβ synergizes with IL-6 to induce pro-inflammatory Th17 cells [29,30]. Moreover, when directly compared to Th1 and Th2 cells, Th17 cells were more likely to overcome the inhibition by Tregs [31]. These data have raised the possibility that Th17 cells are more resistant to regulatory control than other T helper subsets. The molecular basis for this resistance remains obscure.

Thus it is possible that Treg function is normal during autoimmune disease, but the chronic inflammatory environment at the tissue site of autoimmune damage counteracts and overwhelms the suppressive Treg activity. While the issue of Treg fitness during autoimmunity remains a hot topic of discussion, it is possible that multiple pathways lead to the breakdown of peripheral tolerance. It is clear, however, that Tregs function has to be considered and assessed in a context of the inflammatory environment where they operate rather than in the periphery.

Inhibitory cytokines facilitate Treg-mediated control of Teffs and promote the induction of induced Tregs

As discussed in the previous section, the local inflammatory milieu at the site of autoimmune destruction can have a significant effect on Treg function. Cytokines secreted by Tregs, Teffs and other cellular infiltrates contribute to the generation of this environment. Inhibitory cytokines, such as TGFβ and IL-10, can directly inhibit cells that participate in this autoimmune destruction and/or can mediate the generation of induced T regulatory cells (iTregs) [3]. More recently IL-35 has also been shown to directly inhibit T cell proliferation [4,32], although its ability to affect other cell populations or its capacity to mediate/influence the induction of iTregs has yet to be established.

Inhibitory cytokines regulate Teffs

The in vivo role of Treg-derived cytokines in modulating autoimmune diseases has been clearly established. Mice deficient in TGFβ succumb to spontaneous autoimmune disease at 4–5 weeks of age [33,34], while the IL-10 knock out animals are more susceptible to induced autoimmune disease [35]. In TGFβ deficient mice, the dysregulated inflammatory response is alleviated after the depletion of CD4+ and CD8+ T cells [36,37]. Although, Tregs are not the only source of inhibitory cytokines, it has become more evident that Treg secreted cytokines contribute significantly to Treg function in vivo.

TGFβ has been implicated in the function of Tregs in T1D and inflammatory bowel disease (IBD) mouse models [38,39]. Depletion of TGFβ with neutralizing antibodies results in a decrease in both mouse and human Treg function [3941]. T cell transfer and bone marrow chimeric studies revealed that TGFβ has both cell-intrinsic and cell-extrinsic regulatory effects [42,43]. These data show that TGFβ helps to preserve peripheral tolerance by induction of iTregs and maintenance of nTregs in the periphery.

IL-10 is a homodimeric cytokine with a wide range of inhibitory actions. IL-10 is produced by a variety of cells, including monocytes and T cells, and can exert its effects on both myeloid and lymphoid cells [35]. Its regulatory activity is mediated largely through its effects on APCs [44]. Interestingly, IL-10 and IL-10 receptor-deficient mice, unlike their TGFβ counterparts, do not develop spontaneous autoimmune symptoms which only becomes apparent following inflammatory insult. In the absence of IL-10, mice develop colitis in response to some intestinal microorganisms [45,46]. In other murine autoimmune models, such as EAE, mice lacking IL-10 exhibit an exacerbated form of the disease [35]. An increase in IL-10 production by Foxp3+ Tregs is associated with the recovery phase of EAE [8], and transfer of in vitro generated iTregs or exogenously purified natural Tregs was shown to prevent the induction of EAE through the production of IL-10 [47]. IL-10 plays a significant role in intestinal homeostasis. Although, IL-10-deficient Tregs are not devoid of regulatory activity, their function is particularly affected in controlling already established gut inflammation [48], and mice with Treg-specific deletion of IL-10 are susceptible to colitis induced by commensal flora [24]. Similarly to TGFβ, IL-10 can also mediate the generation of an induced regulatory T population, Tr1, that is characterized by secretion of IL-10 [49].

IL-35 is a recently discovered heterodimeric cytokine that is produced by Foxp3+ Tregs and contributes to their suppressive function [32]. IL-35 is composed of two chains, IL-12α (p35) and EBI3 that it shares with two other heterodimeric cytokines IL-12 and IL-27, respectively. IL-35 is required for maximal regulatory function in vivo as Tregs deficient in either chain are unable to control homeostatic T cell expansion and IBD [32]. Given that IL-35 emerged more recently, we still have a limited understanding of its biological activity which has also been complicated by the lack of appropriate tools for its functional dissection. Recombinant IL-35 has proven particularly challenging to generate and purify, compared with IL-12 and IL-27. It is tempting to speculate that the apparent poor stability of IL-35 might underlie important physiological features of this cytokine, such as limited potency over short-range. Alternatively, DCs that secrete IL-12 or IL-27 may be precluded from generating IL-35, due to preferential pairing of IL-12 and IL-27.

It is clearly important to determine the bioactivity of IL-35. Whether IL-35 can inhibit all T helper subsets and other cellular populations, such as B cells, macrophages or DCs, or has more selective targets remains to be determined. Significant insight is likely to be gained from the determination of the IL-35 receptor and its expression pattern. It is tempting to speculate that since IL-35 represents a novel pairing of the IL-12 cytokine chains, its receptor will also be a new combination of the known family receptor chains [50]. Alternatively, the receptor might be composed of novel subunits. If it is the former, a key question will be how cells can translate similar signaling pathways into completely different downstream functional consequences, i.e. stimulatory signaling induced by IL-12 and IL-27 vs inhibitory signal delivered by IL-35. Interestingly, precedence does exist for a similar signaling cascade mediating quite different functional outcomes, as exemplified by the IL-6 and IL-10 receptor which both use STAT3 [51]. Lastly, an open question is whether IL-35 can mediate the generation of an induced regulatory T cell population. This is clearly a feature of the other two inhibitory cytokines IL-10 and TGFβ and thus it remains plausible that IL-35 might have a similar capacity. TGFβ-inuced iTregs (Th3) and IL-10-induced Tr1 clearly have very distinct transcriptional and functional profiles [3,52] and so it is possible that any IL-35-induced regulatory populations may also be quite distinct.

Inhibitory cytokines promote infectious tolerance

It is clear that Foxp3+ Tregs play a major role in most autoimmune diseases. What remains unknown is the relative contribution of natural, thymus-derived Tregs (nTregs) versus iTregs in mediating control of autoimmunity. Furthermore, recent studies suggest that the importance of iTregs in controlling autoimmunity may vary depending on the site of tissue inflammation [4,32].

Recent studies have shown that Tregs and Treg-derived cytokines have long lasting tolerance effects in vivo [4,32]. Even though diabetes onset can be prevented by Treg transfer into NOD mice, the endogenous Foxp3+ Treg population dominates at the site of the original autoimmune response in the pancreas while the transferred population is significantly reduced [38]. In a mouse model of IBD, while TGFβ is essential for downregulating the autoimmune response, Treg-derived TGFβ was not critical for protection [39,42]. This suggests that the main function of TGFβ may be to mediate infectious tolerance (ie. generation of iTregs) which may not necessarily be Treg-derived [53]. It is possible that in order to achieve infectious tolerance several simultaneous signals are required in addition to TGFβ. These can be other inhibitory cytokines, such as IL-10, or cell surface molecules that require cell contact for ligation [54].

Recent findings suggest that different organs or tissues are more suitable or permissive to Treg differentiation due to their cellular and/or molecular composition. Mucosal CD103+ dendritic cells are exceptionally adept at inducing Tregs through production of TGFβ and the Vitamin A metabolite retinoic acid (RA) [55,56]. RA counteracts the effects of inflammatory cytokines and aides in skewing T cells towards a regulatory phenotype [5759]. CD8+CD205+ dendritic cells in the spleen can also mediate iTreg development in part through production of TGFβ [60]. The CNS, however, does not seem to favor the generation of Foxp3+ iTregs [9]. This is in part due to Teff-derived IL-6, which in combination with TGFβ induces Th17 cells rather than Foxp3+ iTregs [29]. DC phenotype is initially induced by microbial interactions leading to the induction of either inflammatory or inhibitory/toleragenic DCs [61]. It is conceivable that the complete Freund’s adjuvant used to induce EAE, which contains mycobacterial cell wall components, results in the generation of DCs that are suboptimal for iTreg generation. In support to this, mice immunized with myelin peptide in incomplete Freund’s adjuvant that lacks Mycobacterium tuberculosis exhibited a decrease in IL-6 production and an increase in antigen specific Foxp3+ T cells in the spleen. However, there was only a modest increase in iTregs and whether these were present in the CNS is unknown [29]. Taken together, these studies suggest that the stimulus received by DCs may be more critical than the particular site or organ that is affected in determining iTreg development. Thus, under alternate stimulatory conditions the CNS might be an acceptable location for iTreg differentiation.

Concluding remarks

Recent advances have placed significant emphasis on dissecting Treg function in autoimmunity and assessing their therapeutic utility. The local inflammatory environment, consisting of specialized APCs, metabolic components, growth factors and inhibitory and/or inflammatory cytokines, can significantly alter the efficacy and generation of Tregs. Given the complexity of Treg function in vivo, several key questions remain before we fully understand molecular and cellular defects that occur in autoimmunity, as they pertain to Tregs, and how this knowledge might be utilized in a clinical setting.

  1. How does inflammation at different tissue sites affect Treg plasticity and how can we counteract the negative effect of inflammatory cytokines on Treg stability? Although we know the minimal requirements for in vitro induction of iTregs (TGFβ, IL-2, TCR stimulation), we have yet to determine what signals are required for stabilization of the Foxp3 locus. This is likely to be key for the therapeutic use of Foxp3+ iTreg. Furthermore, it is still unclear what molecular events mediate nTreg plasticity and how this might be prevented.
  2. Which autoimmune diseases require antigen specificity for successful Treg therapy and what should those antigen targets be? The therapeutic use of in vitro induced populations of regulatory cells, both TGFβ-induced iTregs and IL-10-induced Tr1 cells, is an attractive possibility as one can generate antigen-specific regulatory populations that may effectively home to, and be activated in, the diseased site [49]. For instance, it has recently been shown that T cell migration to the islets is a cell autonomous event suggesting that islet antigen-specific iTregs could be effective mediators of tolerogenic therapy even though there is still debate over the key initiating antigen in T1D [62]. Oral antigen administration results in induction of antigen specific Tregs and is a potentially promising therapeutic approach; however, further clinical trials are warranted before the success of the treatment can be clearly assessed [49,63,64]. However, for many autoimmune diseases the choice of the target antigen remains obscure and its importance ill-defined.
  3. How can we improve the efficacy and safety of cytokine treatments and achieve effective local delivery? Cytokine therapy is possibly one of the most challenging therapies to administer due to pleiotropic activities and potential toxicities. Thus, it is possible that future therapies might be combinatorial and may also include modifications to target cytokines to specific sites and/or modifications to enhance bioactivity or stability. Targeted cytokine delivery, although challenging, could result in improved treatment efficacy and reduced side effects. In one study local administration of IL-10 into the gastrointestinal tract of IBD patients was achieved with the help of genetically modified Lactococcus lactis [65]. Alternatively, gelatin nanoparticles fused with the IL-10 gene has been used to effect local delivery of IL-10 [66]. While much remains to be learnt about IL-35, thus far it appears to be functionally monotropic with seemingly no activating or inflammatory activities [32]. If verified, this focused functionality would be therapeutically desirable as it may have limited in vivo toxicities.

Acknowledgments

DAAV is supported by the Juvenile Diabetes Research Foundation International (1-2004-141 [The Robert and Janice Compton Research Grant, In Honor of Elizabeth S. Compton] and 1-2006-847), the NIH (AI072239), the St Jude Cancer Center Support CORE grant (CA-21765) and the American Lebanese Syrian Associated Charities (ALSAC). MB is supported by a Juvenile Diabetes Research Foundation International post-doctoral fellowship (3-2009-594).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References and recommended reading

Papers of particular interest, published within the past two years, have been highlighted as:

• of special interest

•• of outstanding interest

1. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27. [PubMed]
2. Hellings N, Baree M, Verhoeven C, D'Hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res. 2001;63:290–302. [PubMed]
3. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–532. [PMC free article] [PubMed]
4••. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009;182:6121–6128. This is the first paper to suggest that it is the induction of maximal suppression rather than suppression itself that is critically dependent on target cell contact. [PMC free article] [PubMed]
5. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875–888. [PubMed]
6. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009;27:313–338. [PubMed]
7. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med. 2005;202:1387–1397. [PMC free article] [PubMed]
8. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol. 2005;175:3025–3032. [PubMed]
9. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Backstrom BT, Sobel RA, Wucherpfennig KW, Strom TB, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med. 2007;13:423–431. [PMC free article] [PubMed]
10. McGeachy MJ, Anderton SM. Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine. 2005;32:81–84. [PubMed]
11. Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes. 2008;57:113–123. [PubMed]
12. Mellanby RJ, Thomas D, Phillips JM, Cooke A. Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology. 2007;121:15–28. [PubMed]
13••. D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, Mathis D. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A. 2008;105:19857–19862. This paper takes the spotlight away from possible defects in Treg number and function as a contributing factor in autoimmunity and instead points towards a defect in the effector T cell population, manifest as hyper proliferation and perhaps resistance to Treg control. [PubMed]
14. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54:92–99. [PubMed]
15. Michel L, Berthelot L, Pettre S, Wiertlewski S, Lefrere F, Braudeau C, Brouard S, Soulillou JP, Laplaud DA. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest. 2008;118:3411–3419. [PubMed]
16. Luczynski W, Stasiak-Barmuta A, Urban R, Urban M, Florys B, Hryszko M. Lower percentages of T regulatory cells in children with type 1 diabetes - preliminary report. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2009;15:34–38. [PubMed]
17••. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–697. This study demonstrates that Tregs in pancreatic tissue site of NOD mice are prone to apoptosis due to insufficient levels of IL-2. This is the first study that links local tissue specific IL-2 levels to Treg function. [PMC free article] [PubMed]
18•. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 [PMC free article] [PubMed]
19•. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A. 2009;106:1903–1908. These two papers highlight the potential plasticity of Tregs, especially during autoimmune inflammation. [PubMed]
20. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29:44–56. [PMC free article] [PubMed]
21. Vignali D. How many mechanisms do regulatory T cells need? Eur J Immunol. 2008;38 :908–911. [PubMed]
22•. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–356. [PMC free article] [PubMed]
23•. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595–602. These two papers were the first to suggest that specific transcription factors mediate Treg control of specific T helper subsets. [PMC free article] [PubMed]
24. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR, Jr, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28:546–558. [PubMed]
25. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol. 2003;171:4040–4047. [PubMed]
26. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, Garcia C, Waldmann H, Bach JF, Chatenoud L. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005;54 :1415–1422. [PubMed]
27. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008;181:7350–7355. [PMC free article] [PubMed]
28. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033–1036. [PubMed]
29. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105:18460–18465. [PubMed]
30. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–189. [PubMed]
31. Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM, Shevach EM. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol. 2008;181:1908–1916. [PMC free article] [PubMed]
32••. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569. This is the first study that identifies a novel inhibitory cytokine IL-35 that is highly upregulated in Tregs during their interaction with Teffs. The study shows that IL-35 contributes to Treg function in vivo in a model of colitis. [PubMed]
33. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359:693–699. [PMC free article] [PubMed]
34. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993;90:770–774. [PubMed]
35. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–218. [PMC free article] [PubMed]
36. Kobayashi S, Yoshida K, Ward JM, Letterio JJ, Longenecker G, Yaswen L, Mittleman B, Mozes E, Roberts AB, Karlsson S, et al. Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse. J Immunol. 1999;163:4013–4019. [PubMed]
37. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, Mackall CL, Gress RE, Roberts AB. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest. 1996;98:2109–2119. [PMC free article] [PubMed]
38. Tonkin DR, Haskins K. Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol. 2009;39:1313–1322. [PMC free article] [PubMed]
39. Fahlen L, Read S, Gorelik L, Hurst SD, Coffman RL, Flavell RA, Powrie F. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2005;201:737–746. [PMC free article] [PubMed]
40. Joetham A, Takeda K, Taube C, Miyahara N, Matsubara S, Koya T, Rha YH, Dakhama A, Gelfand EW. Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta. J Immunol. 2007;178:1433–1442. [PubMed]
41. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–4354. [PubMed]
42. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26 :579–591. [PubMed]
43. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity. 2006;25:441–454. [PubMed]
44. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. [PubMed]
45. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263–274. [PubMed]
46. Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, Sordat B, Gibbs VC, Aguet M. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med. 1998;187:571–578. [PMC free article] [PubMed]
47. Selvaraj RK, Geiger TL. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol. 2008;180:2830–2838. [PubMed]
48. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol. 2006;177:5852–5860. [PubMed]
49. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev. 2008;223:391–421. [PubMed]
50. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008;226:248–262. [PMC free article] [PubMed]
51. El Kasmi KC, Smith AM, Williams L, Neale G, Panopoulos AD, Watowich SS, Hacker H, Foxwell BM, Murray PJ. Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol. 2007;179:7215–7219. [PubMed]
52. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–244. [PMC free article] [PubMed]
53•. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach EM. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med. 2008;205:1975–1981. In this study, the authors demonstrate that Treg cells can confer infectious tolerance by inducing new CD4+FoxP3+ T cells in TGFβ-dependant mechanism. [PMC free article] [PubMed]
54•. Maynard CL, Hatton RD, Helms WS, Oliver JR, Stephensen CB, Weaver CT. Contrasting roles for all-trans retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10 genes in developing regulatory T cells. J Exp Med. 2009;206:343–357. In this study the authors report that retinoic acid preferentially induces Foxp3+ Treg cells and inhibits generation of IL-10 producing regulatory cells. [PMC free article] [PubMed]
55. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007;204:1775–1785. [PMC free article] [PubMed]
56. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–1764. [PMC free article] [PubMed]
57•. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P, Belkaid Y, Mathis D, Benoist C. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity. 2008;29:758–770. This study reports that retinoic acid promotes TGFβ induced Treg development by inhibiting the production of a set of cytokines (IFNγ, IL-21, IL-4) produced by activated CD4+CD44+ T cell population. [PMC free article] [PubMed]
58•. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256–260. This is the first study reporting that a metabolite retinoic acid can shift the balance between Foxp3+ regulatory and Th17 inflammatory populations. [PubMed]
59. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med. 2007;204:1765–1774. [PMC free article] [PubMed]
60. Yamazaki S, Dudziak D, Heidkamp GF, Fiorese C, Bonito AJ, Inaba K, Nussenzweig MC, Steinman RM. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol. 2008;181:6923–6933. [PMC free article] [PubMed]
61. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*) Annu Rev Immunol. 2009;27:551–589. [PubMed]
62. Lennon GBM, Burton AR, Vincent E, Arnold PY, Santamaria P, Vignali DA. T cell islet accumulation in type I diabetes is a tightly-regulated, cell-autonomous event. Immunity. 2009 [PMC free article] [PubMed]
63. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007;7:622–632. [PubMed]
64. Brusko T, Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol. 2008;38:931–934. [PubMed]
65. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754–759. [PubMed]
66. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15:1200–1209. [PubMed]